Multi-pharmaceutical companies increase the construction of molecular building blocks of drugs, grabbing a market of 54.6 billion U.S. dollars

 It is reported that recently, the application for the IPO of Beide Pharmaceutical Science and Technology Innovation Board was accepted, and the company plans to raise 434 million yuan to invest in the construction of a regional center for drug molecular blocks
.
According to relevant data estimates, as the main source of revenue for Biopharmaceuticals, the global market for molecular building blocks will reach US$44.
1 billion in 2020
.
So what are the molecular building blocks of drugs? Drug molecules are made up of molecular building blocks.
The so-called molecular building blocks can be understood as the intermediates of drug molecules and the raw materials that constitute drug molecules
.
According to industry insiders, if the drug molecule is a house, the drug molecule building blocks can be roughly understood as the bricks that build a house
.
In the new drug development stage, in order to obtain drug molecules with strong pharmacological activity, low toxic and side effects, and good absorption and distribution in the human body, it is necessary to synthesize thousands of molecular compounds, and then screen and optimize them.
In this process, the molecules Building blocks play a key role, because molecular building blocks can directly affect or even determine the overall physical, chemical and biological properties of the molecule
.
According to the chemical molecular structure, pharmaceutical molecular building blocks can be divided into three categories: heterocyclic ring, benzene ring and aliphatic
.
In recent years, with the steady growth of the global pharmaceutical R&D industry, the pharmaceutical molecular building block R&D and production industry has a broad market prospect
.
According to statistics, 30% of the global pharmaceutical R&D expenditure is used for the purchase and outsourcing of pharmaceutical molecular building blocks.
Based on this estimate, the global pharmaceutical molecular building block market size in 2020 may reach 44.
1 billion U.
S.
dollars, after excluding labor costs.
By 2026, this market size may reach 54.
6 billion U.
S.
dollars
.
Facing the broad market prospects, some companies are stepping up their deployment, and Beat Medicine is one of them
.
It is reported that the main products of Biopharmaceuticals are drug molecular building blocks and scientific reagents.
In order to better invest in the construction of drug molecular building regional centers and other projects, Biopharmaceuticals sprinted for an IPO on the Sci-tech Innovation Board recently, and plans to raise 434 million yuan to increase this.
Plate
.
The data shows that as one of the independent brand suppliers of drug molecular building blocks, Beat Medicine has seen significant growth in performance in recent years.
The compound growth rate of the company’s revenue in the past three years has reached nearly 55%.

.
In the first three quarters of 2021, Beat Pharmaceuticals achieved operating income of 427 million yuan, and net profit attributable to owners of the parent company was 66,700,900 yuan
.
In recent years, the R&D advantages of China's innovative pharmaceutical companies have gradually emerged, but when it comes to the development of new drugs, they cannot do without the molecular building blocks of drugs in the early research period.
This shows the importance of molecular building blocks
.
It is understood that in addition to the above-mentioned Beat Medicine is continuously increasing the size of drug molecular building blocks and achieving significant results, Yaoshi Technology is also deeply engaged in the research and development and production of molecular building blocks.
Its drug molecular building block library is not only more than 80,000 in scale, but also It is in the first echelon of the world, and can deliver products within 1-2 weeks, effectively assisting the research and development of pharmaceutical companies
.
In addition, Haoyuan Pharmaceutical is also a representative enterprise in the field of molecular building blocks in China.
The company's molecular building blocks cover quinolines, azaindoles, tetralones, piperazines, pyrrolidines, and cyclobutanes.
Products of chemical structure types such as class, spiro ring, etc.
, have the ability to actively design and develop unique molecular building blocks and tool compound products with novel structures
.
Data show that in the past five or six years, benefiting from the boom in the pharmaceutical molecular building block industry, the company has also ushered in a period of rapid development, and its performance scale has continued to rise; among them, the company’s operating income has a compound annual growth rate of 134 from 2015 to 2020.
%, the compound annual growth rate of net profit attributable to the parent after deduction is as high as 173%
.
Analysts pointed out that molecular blocks are the entrance to R&D, with high technical barriers and relatively friendly to sellers
.
Molecular building block suppliers can enjoy a higher market premium by actively designing and developing unique molecular building blocks and tool compound product series with novel structures; at the same time, molecular building block business has high viscosity, and customers generally will not easily change suppliers
.
In this regard, some companies said that in the future, they will focus on the main business of drug molecular building blocks, look for more possibilities that are conducive to development, grow together with new drug research and development institutions, overcome new drug research and development problems, and promote the development of the innovative drug market
.